WAVE Life Sciences (NASDAQ:WVE) Hits New 1-Year Low - Time to Sell?

WAVE Life Sciences logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • WAVE Life Sciences shares hit a new 52-week low, falling to $2.74 during Thursday trading; the stock’s 50-day and 200-day moving averages were $3.61 and $6.82, respectively.
  • Analyst sentiment remains broadly positive despite the price decline: MarketBeat reports a “Moderate Buy” consensus and an average target of $20.44, though ratings range from strong buy to sell.
  • In its latest reported quarter, WAVE posted an adjusted loss of $0.30 per share, better than estimates of $0.33, and revenue of $13.16 million versus expectations of $4.51 million. Analysts forecast a full-year loss of $1.08 per share.
  • Five stocks we like better than WAVE Life Sciences.

Shares of WAVE Life Sciences Ltd. (NASDAQ:WVE - Get Free Report) hit a new 52-week low during mid-day trading on Thursday. The company traded as low as $2.74 and last traded at $2.7350, with a volume of 446,056 shares. The stock had previously closed at $2.77.

Analyst Upgrades and Downgrades

WVE has been the topic of several recent research reports. B. Riley Financial reaffirmed a "buy" rating and set a $18.00 price objective on shares of WAVE Life Sciences in a report on Monday, November 9th. UBS Group started coverage on WAVE Life Sciences in a report on Thursday, October 15th. They issued a "buy" rating and a $11.00 price target for the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of WAVE Life Sciences in a research report on Thursday, October 15th. Ladenburg Thalmann & Co. Inc. initiated coverage on WAVE Life Sciences in a research report on Thursday, October 1st. They set a "buy" rating and a $10.00 target price on the stock. Finally, HC Wainwright initiated coverage on WAVE Life Sciences in a research report on Wednesday, October 28th. They issued a "strong-buy" rating on the stock. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, WAVE Life Sciences has an average rating of "Moderate Buy" and an average target price of $20.44.

Check Out Our Latest Research Report on WAVE Life Sciences

WAVE Life Sciences Price Performance

The firm has a market capitalization of $535.48 million, a PE ratio of -2.55 and a beta of -1.40. The company's fifty day simple moving average is $3.61 and its 200-day simple moving average is $6.82.

WAVE Life Sciences (NASDAQ:WVE - Get Free Report) last announced its earnings results on Wednesday, October 28th. The company reported ($0.30) EPS for the quarter, beating analysts' consensus estimates of ($0.33) by $0.03. WAVE Life Sciences had a negative return on equity of 44.66% and a negative net margin of 296.86%. The business had revenue of $13.16 million during the quarter, compared to analysts' expectations of $4.51 million. Analysts forecast that WAVE Life Sciences Ltd. will post -1.08 earnings per share for the current year.

Hedge Funds Weigh In On WAVE Life Sciences

A number of institutional investors have recently added to or reduced their stakes in the stock. FORA Capital LLC acquired a new position in shares of WAVE Life Sciences during the 3rd quarter valued at about $41,000. R Squared Ltd acquired a new position in WAVE Life Sciences during the 3rd quarter worth about $48,000. AlphaGrep UK Ltd acquired a new position in shares of WAVE Life Sciences in the second quarter valued at approximately $78,000. First Trust Advisors LP grew its stake in shares of WAVE Life Sciences by 15.7% in the first quarter. First Trust Advisors LP now owns 13,518 shares of the company's stock worth $98,000 after acquiring an additional 1,830 shares in the last quarter. Finally, Bessemer Group Inc. increased its holdings in WAVE Life Sciences by 118.4% during the 3rd quarter. Bessemer Group Inc. now owns 15,550 shares of the company's stock worth $58,000 after purchasing an additional 8,430 shares during the period. Hedge funds and other institutional investors own 89.73% of the company's stock.

WAVE Life Sciences Company Profile

(Get Free Report)

WAVE Life Sciences Ltd. is a biotechnology company developing RNA-based medicines for genetically defined diseases. Founded in 2012, the company is headquartered in Cambridge, Massachusetts, and uses its oligonucleotide chemistry and drug-design capabilities to develop treatments intended to alter or regulate gene expression. Its research includes antisense oligonucleotide therapies and RNA-editing approaches. Programs have targeted conditions such as Huntington's disease and alpha-1 antitrypsin deficiency, with the latter exploring RNA editing to address a disease-causing genetic variant.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in WAVE Life Sciences Right Now?

Before you consider WAVE Life Sciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and WAVE Life Sciences wasn't on the list.

While WAVE Life Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines